Denali Therapeutics (DNLI) News Today

Denali Therapeutics Inc. (NASDAQ:DNLI) shares moved today on a flurry of analyst revisions and insider activity. Key factors driving sentiment include:

• Positive Sentiment: Shares jumped after the stock traded up 11.1% on renewed buy interest. Trading 11.1% Higher - Still a Buy?
• Positive Sentiment: Wedbush raised its FY2025 EPS estimate, forecasting slightly smaller losses for the year.
• Positive Sentiment: William Blair boosted its Q3 2025 EPS forecast, projecting narrower quarterly losses and reiterating a strong-buy rating.
• Negative Sentiment: B. Riley cut its FY2029 EPS estimate from $0.27 to $0.19, lowering long-term profit expectations.
• Negative Sentiment: Leerink Partners reduced its Q4 2025 loss forecast, now expecting ($0.82) per share vs. a prior ($0.80) estimate.
• Negative Sentiment: HC Wainwright trimmed both its FY2025 and FY2028 EPS projections, anticipating deeper near-term losses and slightly lower 2028 earnings.
• Negative Sentiment: Cantor Fitzgerald lowered its FY2025 EPS forecast to ($3.01) from ($2.97), signaling wider annual losses.
• Negative Sentiment: Insider Carole Ho sold 806 shares, slightly reducing her stake in the company. Insider Carole Ho Sells Shares

Overall, DNLI shares rallied today despite mixed analyst revisions and insider selling, as investors focused on upward revisions and strong buy signals.